title: The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer.
abstract: BACKGROUND
  The aim of this study was to determine any correlation between the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines and the matrix metalloproteinase 9 (MMP-9) expression in primary colorectal cancer tissues.
  
  
  METHODS
  The data on 307 patients with colorectal cancer at stage II or III, who underwent potentially curative resection with lymphadenectomy, were reviewed. Of these, 188 received postoperative administration of oral fluoropyrimidines such as UFT and 5'-DFUR (chemotherapy group), while the other 119 patients underwent surgery alone (surgery-alone group). Immunostaining for MMP-9 was performed using surgical specimens of all 307 primary tumors and 18 recurrent tumors.
  
  
  RESULTS
  Overall, MMP-9 was positively expressed in the primary tumor in 44% of patients. Multivariate analysis revealed that the MMP-9 expression was a worse prognostic factor with a second highest hazard ratio for recurrence. The disease-free survival rate in the chemotherapy group was significantly higher than that in the surgery-alone group. However, no significant difference in disease-free survival rate between the two groups was found in patients with a tumor positive for MMP-9. There was a strong positive correlation of MMP-9 expression between the primary tumors and the recurrent liver or lung tumors.
  
  
  CONCLUSIONS
  The efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines such as UFT and 5'-DFUR may not be as great for patients with a tumor positive for MMP-9 having a greater risk to postoperative recurrence.
authors.affiliation: Department of Surgery, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan. yogata@med.kurume-u.ac.jp
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Ogata
authors.forename: Keiko
authors.initials: K
authors.lastname: Matono
authors.forename: Teruo
authors.initials: T
authors.lastname: Sasatomi
authors.forename: Nobuya
authors.initials: N
authors.lastname: Ishibashi
authors.forename: Akira
authors.initials: A
authors.lastname: Ohkita
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Mizobe
authors.forename: Shujiro
authors.initials: S
authors.lastname: Ogo
authors.forename: Satoru
authors.initials: S
authors.lastname: Ikeda
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Ozasa
authors.forename: Kazuo
authors.initials: K
authors.lastname: Shirouzu
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000601:surgery; D018572:Disease-Free Survival; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D006801:Humans; D008113:Liver Neoplasms / Q000201:enzymology / Q000556:secondary / Q000628:therapy; D008175:Lung Neoplasms / Q000201:enzymology / Q000556:secondary / Q000628:therapy; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism*; D009361:Neoplasm Invasiveness / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000201:enzymology / Q000601:surgery; D009367:Neoplasm Staging; D011184:Postoperative Period; D012189:Retrospective Studies; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
chemical_list: D005467:Floxuridine; D005641:Tegafur; D014498:Uracil; D020780:Matrix Metalloproteinase 9; C025034:doxifluridine